ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the European Commission (EC) to treat adults with ...

Amvuttra is the first and only RNA interference (RNAi) therapeutic approved by the EC for both the cardiomyopathy and the ...

Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

BridgeBio's Attruby surpasses expectations with booming Q1 revenue and strong market positioning. Read why BBIO stock is ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

BMO Capital Markets analyst Kostas Biliouris reiterated a Hold rating on BridgeBio Pharma Inc. (NASDAQ:BBIO) with an ...

The world just got a little closer. The new iGlobal Radio App is now live, offering users a dynamic way to connect with radio ...

Spinal Simplicity, a medical device company dedicated to creating simple, innovative procedure solutions, is proud to announce the launch of the Patriot-SI implant as a stand-alone solution for ...

On June 3, BMO Capital Markets analyst Kostas Biliouris reiterated a Hold rating on BridgeBio Pharma Inc. (NASDAQ:BBIO) with an unchanged price target of $37. His view reflects growing concerns ...

Vutrisiran is already approved as Amvuttra to treat rare disease hereditary ATTR amyloidosis, so approval in Stargardt disease would prompt the pricing negotiation mechanism. Alnylam's earlier ...